Table 2.
Cancer Characteristics of Study Sample by Cancer Site and Race/Ethnicity from Kaiser Permanente Northern California, 1997–2015 (N=83,278)
| Patient group | American Indian and Alaskan Natives (582) |
Non-Hispanic White (82,696) |
||
|---|---|---|---|---|
| n | % | n | % | |
| All Cancer patients: | ||||
| AJCC Stage | ||||
| Localized | 310 | 53.3 | 46,852 | 56.7 |
| Regional | 146 | 25.1 | 18,681 | 22.6 |
| Distant | 113 | 19.4 | 15,252 | 18.4 |
| Unknown | 13 | 2.2 | 1,911 | 2.3 |
| Treatment | ||||
| Definitive surgery | 345 | 59.3 | 46,712 | 56.5 |
| Chemotherapy | 194 | 33.3 | 21,623 | 26.2 |
| Radiation therapy | 154 | 26.5 | 21,926 | 26.5 |
| Hormone therapy | 111 | 19.1 | 18,674 | 22.6 |
| Vital Status | ||||
| Deceased | 268 | 46.1 | 38,231 | 46.2 |
| Alive | 314 | 54.0 | 44,465 | 53.8 |
|
| ||||
| Prostate Cancer patients: | ||||
| Follow-up time, years Median (IQR) | 4.8 | (2.4–9.1) | 6.5 | (3.4–10.4) |
| AJCC Stage | ||||
| Localized | 119 | 81.0 | 21,489 | 82.0 |
| Regional | 15 | 10.2 | 2,391 | 9.1 |
| Distant | 7 | 4.8 | 1,389 | 5.3 |
| Unknown | 6 | 4.1 | 936 | 3.6 |
| Treatment | ||||
| Definitive surgery | 31 | 21.1 | 7,005 | 26.7 |
| Chemotherapy | 0 | 0.0 | 100 | 0.4 |
| Radiation therapy | 50 | 34.0 | 6,860 | 26.2 |
| Hormone therapy | 40 | 27.2 | 6,738 | 25.7 |
| Vital Status | ||||
| Deceased | 43 | 29.3 | 8,118 | 31.0 |
| Alive | 104 | 70.8 | 18,087 | 69.0 |
|
| ||||
| Breast Cancer Patients: | ||||
| Follow-up time, years Median (IQR) | 4.5 | (2.4–8.0) | 5.8 | (2.9–10.2) |
| AJCC Stage | ||||
| Localized | 112 | 62.6 | 17,028 | 66.7 |
| Regional | 59 | 33.0 | 7,336 | 28.7 |
| Distant | 7 | 3.9 | 952 | 3.7 |
| Unknown | 1 | 0.6 | 232 | 0.9 |
| Treatment | ||||
| Definitive surgery | 170 | 95.0 | 24,066 | 94.2 |
| Chemotherapy | 75 | 41.9 | 9,749 | 38.2 |
| Radiation therapy | 48 | 26.8 | 9,018 | 35.3 |
| Hormone therapy | 71 | 39.7 | 11,872 | 46.5 |
| Vital Status | ||||
| Deceased | 55 | 30.7 | 7,462 | 29.2 |
| Alive | 124 | 69.3 | 18,086 | 70.8 |
|
| ||||
| Lung Cancer Patients: | ||||
| Follow-up time, years Median (IQR) | 0.8 | (0.3–2.3) | 0.7 | (0.2–1.9) |
| AJCC Stage | ||||
| Localized | 22 | 18.0 | 2,748 | 16.2 |
| Regional | 25 | 20.5 | 3,746 | 22.1 |
| Distant | 75 | 61.5 | 10,049 | 59.4 |
| Unknown | 0 | 0.0 | 390 | 2.3 |
| Treatment | ||||
| Definitive surgery | 33 | 27.1 | 3,595 | 21.2 |
| Chemotherapy | 64 | 52.5 | 6,548 | 38.7 |
| Radiation therapy | 27 | 22.1 | 4,532 | 26.8 |
| Hormone therapy | 0 | 0.0 | 53 | 0.3 |
| Vital Status | ||||
| Deceased | 100 | 82.0 | 14,997 | 88.6 |
| Alive | 22 | 18.0 | 1,936 | 11.4 |
|
| ||||
| Colorectal Cancer Patients: | ||||
| Follow-up time, years Median (IQR) | 3.2 | (1.1–7.4) | 3.3 | (1.2–7.4) |
| AJCC Stage | ||||
| Localized | 57 | 42.5 | 5,587 | 39.9 |
| Regional | 47 | 35.1 | 5,208 | 37.2 |
| Distant | 24 | 17.9 | 2,862 | 20.4 |
| Unknown | 6 | 4.5 | 353 | 2.5 |
| Treatment | ||||
| Definitive surgery | 111 | 82.8 | 12,046 | 86.0 |
| Chemotherapy | 55 | 41.0 | 5,226 | 37.3 |
| Radiation therapy | 29 | 21.6 | 1,516 | 10.8 |
| Hormone therapy | 0 | 0.0 | 11 | 0.1 |
| Vital Status | ||||
| Deceased | 70 | 52.2 | 7,654 | 54.6 |
| Alive | 64 | 47.8 | 6,356 | 45.4 |
Proportions may not equal 100 due to rounding